PM Srettha inspects ’30-Baht Plus’ healthcare policy
Prime Minister Srettha Thavisin spearheaded the inspection of the Phra Ajarn Mun Bhuridatto Hospital’s construction progress and closely monitored the implementation of the 30-baht Plus healthcare policy in Sakon Nakhon Province.
The Phra Ajarn Mun Bhuridatto Hospital stands as a beacon of hope, catering to a vast population, including residents from neighbouring provinces. The relentless pursuit of excellence has driven ongoing enhancements within the hospital to deliver optimised services efficiently.
PM Srettha’s vigilant oversight extends to the rollout of the pioneering healthcare initiative, where citizens can access treatment for a mere 30-baht Plus or with just their ID card. This policy, orchestrated by the Ministry of Public Health, is poised to extend its reach to Sakon Nakhon Province imminently, following successful trials in Phrae, Roi Et, Phetchaburi, and Narathiwat.
Furthermore, as March approaches, the government gears up for the project’s ambitious second phase, which will encompass eight additional provinces. Phetchabun, Nakhon Sawan, Sing Buri, Sa Kaeo, Nong Bua Lamphu, Nakhon Ratchasima, Amnat Charoen, and Phang Nga are all slated to benefit from the expansion, promising enhanced healthcare accessibility for millions across Thailand, reported Pattaya Mail.
In related news, the Health Service Support Department joined forces with the Office of Insurance Commission and insurance providers to integrate surrogacy into the health insurance scheme. This move comes in response to Thailand’s plummeting birth rates and the looming spectre of an ageing population.
According to Dr Sura Wisedsak, the department’s director-general, a whopping 114 hospitals and clinics across Thailand are currently offering Assisted Reproduction Technology (ART) to couples grappling with conception challenges or pregnancy complications.
In other news, Thonburi Healthcare Group Plc (THG) is set to broaden its hospital operations in Myanmar in response to the rising demand for medical treatments. The executive chief, Tanatip Suppradit, disclosed that a feasibility study on the new investment is currently underway with results anticipated imminently.
